Mega Genomics Limited (HKG:6667)

Market Cap	1.61B -22.7%
Revenue (ttm)	174.76M +10.1%
Net Income	47.94M +203.0%
EPS	0.23 +216.9%
Shares Out	224.30M
PE Ratio	30.75
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,200
Average Volume	21,330
Open	7.30
Previous Close	7.25
Day's Range	7.20 - 7.30
52-Week Range	5.98 - 11.98
Beta	0.99
RSI	46.97
Earnings Date	Jan 30, 2026

About Mega Genomics

Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services, including brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; and cardiovascular and cerebrovascular disease risk...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Employees: 214
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6667

Financial Performance

In 2024, Mega Genomics's revenue was 164.23 million, an increase of 8.54% compared to the previous year's 151.30 million. Earnings were 45.05 million, an increase of 49.96%.

Financial numbers in CNY